广东东阳光科技控股股份有限公司 简式权益变动报告书 上市公司名称：广东东阳光科技控股股份有限公司 股票上市地点：上海证券交易所 股票简称：东阳光 股票代码：600673 信息披露义务人：元素沅溸私募证券投资基金 管理人：重庆元素私募证券投资基金管理有限公司 住所/通讯地址：重庆市江北区庆云路 16 号 27-11 股份变动性质：股份减少（协议转让） 签署日期：二〇二四年十二月二十三日 1 信息披露义务人声明 一、本报告书依据《中华人民共和国证券法》《上市公司收购管理办法》《公 开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》及其 他相关的法律、法规和规范性文件编制； 二、信息披露义务人签署本报告已经获得必要的授权和批准，其履行亦不违 反信息披露义务人公司章程或内部规则中的任何条款，或与之相冲突； 三、依据《中华人民共和国证券法》《上市公司收购管理办法》的规定，本 报告书已全面披露信息披露义务人在东阳光拥有权益的股份变动情况； 截至本报告书签署之日，除本报告书披露的持股信息外，信息披露义务人未 通过任何其他方式增加或减少其在东阳光拥有权益的股份； 四、本次权益变动是根据本报告所载明的资料进 ...

广东东阳光科技控股股份有限公司 简式权益变动报告书 上市公司名称：广东东阳光科技控股股份有限公司 股票上市地点：上海证券交易所 股票简称：东阳光 股票代码：600673 信息披露义务人：苏州丰禾盈晖企业管理合伙企业（有限合伙） 主要经营场所：苏州独墅湖科教创新区（东区）东石泾港路 2 号润港产业园 6 号 楼 10 层（1002）室 股份变动性质：股份增加（协议转让） 签署日期：二〇二四年十二月二十三日 1 截至本报告书签署之日，除本报告书披露的持股信息外，信息披露义务人未 通过任何其他方式增加或减少其在东阳光拥有权益的股份； 四、本次权益变动是根据本报告所载明的资料进行的。信息披露义务人没有 委托或者授权其它任何人提供未在本报告书列载的信息和对本报告书做出任何 解释或者说明； 五、信息披露义务人承诺本报告书不存在虚假记载、误导性陈述或重大遗漏， 并对其真实性、准确性、完整性承担法律责任； 六、本次权益变动涉及协议转让事项尚需取得上海证券交易所的合规确认、 向中国证券登记结算有限责任公司上海分公司申请办理股份转让过户登记以及 按照其他相关法律法规的要求如需履行的程序。目前相关方正在为履行相关审批 程序进行准备 ...

Core Insights - The fundamental characteristic of new productive forces is innovation, with the company's core competitiveness being its strong R&D capabilities [1] - The company has established a national-level postdoctoral research station and has been recognized as a national enterprise technology center, indicating its commitment to attracting high-tech talent and fostering innovation [1][2] - The company is actively upgrading its products and exploring new fields, particularly in strategic emerging industries such as new energy and advanced manufacturing [1][5] Product Development - The company has launched a new generation of electrode foil products called "stacked foil," which offers significant advantages over traditional etched foil, making it suitable for various types of capacitors and addressing industry pain points [2] - The company is strategically positioning itself in the cooling solutions market for AI data centers and has applied for multiple patents in the field of fluorinated cooling liquids since 2016 [2] Market Positioning - With the explosion of the AI market, the company aims to leverage its industry chain advantages, market resources, and technological reserves to capture market share and benefit from industry growth [3] - The company has segmented its four major industries into independent business units to enhance operational efficiency and has established a "Key Accounts Division" to cater to large clients [4] Industry Trends - The government has emphasized the acceleration of new productive forces as a key task for 2024, aligning with the company's development strategy [5] - The company has successfully diversified its operations, becoming a leading player in multiple segments, including electronic components and high-end aluminum foil [6][8] Supply Chain and Production - The company has developed a complete industrial chain from upstream to downstream, including the production of aluminum foil, fluorinated chemicals, and energy materials, enhancing its market competitiveness [9][11] - The company has established a chlor-alkali chemical plant to ensure a stable supply chain for raw materials, further extending its reach into the chemical industry [9] Management and Strategy - The company has undergone significant management reforms to adapt to its diversified operations and the demands of a "chain-based operation" model, focusing on collaboration across various industry chains [12]

证券代码：600673 证券简称：东阳光 编号：临 2024-79 号 广东东阳光科技控股股份有限公司 关于控股股东之一致行动人部分股份解质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广东东阳光科技控股股份有限公司（以下简称"公司"）于近日收到控股股 东之一致行动人乳源阳之光的通知，获悉其将其持有的公司部分无限售流通股进 行了解质押，具体事项如下： | 股东名称 | 乳源阳之光铝业发展有限公司 | | --- | --- | | 本次解质押股数 | 15,090,544 股 | | 占其所持股份比例 | 11.78% | | 占公司总股本比例 | 0.50% | | 解质押时间 | 2024 年 12 月 11 日 | | 持股数量 | 128,058,819 股 | | 持股比例 | 4.25% | | 剩余被质押股数 | 61,090,543 股 | | 剩余被质押股数占其所持有股份比例 | 47.71% | | 剩余被质押股数占公司总股本比例 | 2.03% | 一、本次股份解质押基本情况 乳源阳之光本次解 ...

Core Viewpoint - Dongyang Sunshine Pharmaceutical has submitted its listing application to the Hong Kong Stock Exchange, with CICC serving as the sole sponsor [1] Group 1: Company Overview - Established in 2003, Dongyang Sunshine Pharmaceutical is a comprehensive pharmaceutical company engaged in drug research and development, production, and commercialization [1] - The company focuses on innovative drugs, improved new drugs, generic drugs, and biosimilars, primarily targeting infection, chronic diseases, and tumors [1] - Dongyang Sunshine has a leading R&D platform, international standard production facilities, and a global sales network [1] Group 2: Research and Development - As of June 30, 2024, the company has 147 approved drugs globally and over 100 drugs in development, including 45 first-class innovative drugs [1] - Dongyang Sunshine is one of the few Chinese pharmaceutical companies that have successfully launched a first-class innovative drug through independent R&D and has three first-class innovative drugs under application for listing [1] Group 3: Market Performance - The company has shown strong performance in the anti-infection drug sector, with its product Kewi R (Oseltamivir Phosphate) capturing 64.8% of the Oseltamivir market in China in 2023 [1] - Dongyang Sunshine possesses a vast sales network covering China, Europe, and North America [1]

证券代码：600673 证券简称：东阳光 编号：临 2024-78 号 广东东阳光科技控股股份有限公司 二、回购股份的进展情况 关于调整回购股份方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次调整回购方案的具体内容：将回购价格由"不超过人民币 9.10 元/ 股"调整为"不超过人民币 12.00 元/股"；将回购资金来源由"公司自有资 金"调整为"自有资金和专项贷款资金"。除上述调整外，回购股份方案的其 他内容未发生变化。 ● 本次调整回购股份方案已经公司第十二届董事会第六次会议审议通过， 无须提交股东大会审议。 ● 本次股票回购专项贷款额度不代表公司对回购金额的承诺，具体回购股 份的金额以回购期满时实际回购的金额为准。 一、回购股份的基本情况 公司于 2024 年 7 月 25 日召开公司第十二届董事会第二次会议，审议通过 了《关于以集中竞价方式回购股份方案的议案》，同意公司以自有资金通过集 中竞价交易方式回购公司股份，回购价格不超过 9.10 元/股，回购金额为不低 于人民币 2 亿元且 ...

Company and Industry Summary Company Overview - The company operates in multiple segments, including electronic components, chemical new materials, and energy materials, with a focus on vertical integration across its supply chains [2][3][4] Key Business Segments 1. **Electronic Components** - This segment includes aluminum electrolytic capacitors and upstream materials such as electrode foil and aluminum foil [2][3] - The demand for aluminum electrolytic capacitors is driven by growth in the electronics industry, particularly in consumer electronics, 5G, and new energy vehicles [9] - The company has a production capacity of approximately 30 billion for aluminum electrolytic capacitors, which is a core asset [11] 2. **Chemical New Materials** - This includes refrigerants and PVDF (polyvinylidene fluoride) [3][4] - The company is expanding its production capabilities in this area, with a focus on high-end products in collaboration with partners [13] 3. **Energy Materials** - This segment focuses on materials related to lithium batteries and coal mining [3][4] - The company has established partnerships to enhance its supply chain from raw materials to end products [14] Market Dynamics - The company anticipates improvements in the capacitor and refrigerant industries in 2024, following a challenging 2023 [1] - The pricing for refrigerants has shown significant increases, with export prices nearing domestic prices, which is expected to enhance profitability [12] - The overall market for aluminum electrolytic capacitors is projected to grow, with domestic companies like the company competing against established Japanese firms [9] Financial Performance - Historical stock performance indicates significant growth phases, particularly from 2006 to 2007 and 2009 to 2011, driven by industry recovery and increased demand [6][7] - The company is expected to see a notable increase in profits in 2024, with estimates suggesting contributions exceeding 1 billion from various segments [16] Management and Strategy - The company is led by a family-controlled management team, with a strong emphasis on R&D capabilities [8][16] - The strategy involves vertical integration, allowing the company to control costs and enhance product offerings across its supply chains [5][19] Risks and Considerations - There are concerns regarding potential competition between the company's upstream and downstream operations, particularly in the capacitor market [18][19] - The company is navigating a cyclical industry landscape, with fluctuations in demand and pricing impacting overall performance [13][20] Conclusion - The company is positioned for growth in 2024, with strong fundamentals across its business segments and a focus on innovation and market expansion [17][21]

证券代码：600673 证券简称：东阳光 编号：临 2024-77 号 广东东阳光科技控股股份有限公司 重要内容提示: 关于控股股东及其一致行动人部分股份解质押及质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 控股股东深圳市东阳光实业发展有限公司（以下简称"深圳东阳光实业"） 持有本公司股份 582,469,389 股，占公司总股本的 19.33%；截至本次股份质押完 成后，深圳东阳光实业持有本公司股份累计质押数量 569,798,054 股，占其持股 数量的 97.82%。 控股股东之一致行动人宜昌东阳光药业股份有限公司（以下简称"宜昌 药业股份"）持有本公司股份 545,023,350 股，占公司总股本的 18.08%；截至本 次股份解质押及质押完成后，宜昌药业股份持有本公司股份累计质押数量 495,000,000 股，占其持股数量的 90.82%。 截至本公告披露日，公司控股股东累计质押股数数量为 569,798,054 股， 占其持股数量的 97.82%；控股股东及其一致行动人累计质押股数数量为 1,205 ...

证券代码：600673 证券简称：东阳光 公告编号：临 2024-76 号 广东东阳光科技控股股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广东东阳光科技控股股份有限公司（以下简称"公司"）于 2024 年 7 月 25 日 召开公司第十二届董事会第二次会议，审议通过了《关于以集中竞价方式回购股份 方案的议案》，同意公司以自有资金通过集中竞价交易方式回购公司股份，回购价 格不超过 9.10 元/股，回购金额为不低于人民币 2 亿元且不超过人民币 4 亿元， 回购期限为自董事会审议通过本次回购股份方案之日起 6 个月内，详情请见公司 于 2024 年 7 月 26 日在上海证券交易所网站 www.sse.com.cn 上发布的《东阳光关 于以集中竞价交易方式回购股份的回购报告书》（临 2024-50 号）。 二、回购股份的进展情况 2024 年 11 月，公司未实施回购。 截至 2024 年 11 月月底，公司已累计回购股份 8,358,384 股，占公司总股本 的比例为 ...

重要内容提示: 证券代码：600673 证券简称：东阳光 编号：临 2024-75 号 广东东阳光科技控股股份有限公司 关于控股股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 控股股东深圳市东阳光实业发展有限公司（以下简称"深圳东阳光实业"） 持有本公司股份 582,469,389 股，占公司总股本的 19.33%；截至本次股份质押完 成后，深圳东阳光实业持有本公司股份累计质押数量 519,798,054 股，占其持股 数量的 89.24%。 截至本公告披露日，公司控股股东累计质押股数数量为 519,798,054 股， 占其持股数量比例为 89.24%；控股股东及其一致行动人累计质押股数数量为 1,205,979,141 股，占合计持股数量比例为 77.66%。 一、上市公司股份质押 广东东阳光科技控股股份有限公司（以下简称"公司"）于近日收到控股股 东深圳东阳光实业的通知，获悉其将其持有的公司部分无限售流通股进行了质押， 具体事项如下： | 股东名称 | 是否 为控 | 本次质押股数 | 是否 | ...